1310 Chesapeake Terrace
379 articles with Accuray Inc.
Hong Kong Sanatorium & Hospital Signs Agreement at ESTRO to Acquire the Synchrony® Motion Tracking and Correction Technology for the Accuray Radixact® System
Hospital is the First in Asia to Procure Synchrony for Radixact, Furthering Its Goal to Use Advanced Medical Technology to Improve Cancer Treatments
Only Radiotherapy System with Helical Delivery Capability and Intrafraction Motion Synchronization Functionality, Offering Expanded Versatility and Increased Precision in the Treatment of Simple to Complex Tumors
Accuray Incorporated reported its financial results for the third quarter of fiscal 2019 ended March 31, 2019.
Phase 3 Randomized Trial Data Shows SBRT has Similar Acute Safety Profile to Conventional Radiation Therapy in Patients with Localized Prostate Cancer
Data Presented at the 2019 Genitourinary Cancers Symposium Reinforces Benefits of Short Course of Treatment Using Stereotactic Body Radiation Therapy for Low- or Intermediate-Risk Prostate Cancer
Accuray Inc. (NASDAQ: ARAY) today reported its financial results for the second quarter of fiscal 2019 ended December 31, 2018.
The Urology Group Surpasses 1,600 Prostate Cancer Patients Treated with the Accuray CyberKnife® M6™ System
According to the American Cancer Society, prostate cancer is the most common cancer in American men other than skin cancer.
Management will host a conference call to review the results at 1:30 p.m. PT/4:30 p.m. ET on the same day.
Accuray Incorporated announced today that the Company will present at the J.P. Morgan 37th Annual Healthcare Conference on Wednesday, January 9, 2019 at the Westin St. Francis Hotel in San Francisco. Attendance at the conference is by invitation only.
Accuray Incorporated (NASDAQ: ARAY) announced today that its Board of Directors has named Shig Hamamatsu as senior vice president, chief financial officer effective immediately.
Accuray Showcases Radiation Therapy Innovations Designed to Improve What's Possible for Patients at ASTRO 2018
Meeting attendees can visit Accuray at booth #2511 on October 21 - 23, 2018 in San Antonio, Texas
Management will host a conference call to review the first quarter results at 1:30 p.m. PT/4:30 p.m. ET on October 30, 2018.
Technische Universität München Hospital is First in Germany to Treat Cancer Patients with Accuray Radixact® System
Versatile, Easy-to-Use System Offers Patients Access to Technologically Advanced Cancer Care
Adoption of Innovative Radiation Therapy Technology Reinforces South Asian Cancer Center's Position as Pioneer in Patient Care
Internationally Renowned Centre in Cambridge, England is First NHS Hospital to Install the Innovative Radiation Therapy System
Accuray Incorporated will report results for its fourth quarter and fiscal year 2018 ended June 30, 2018 on Thursday, August 16, 2018 after the market close.
Accuray Inc.(NASDAQ: ARAY) announced today the appointment of Joseph E. Whitters to the company's Board of Directors, effective as of July 16, 2018. In addition, he will serve on the Board's Audit Committee. With Mr. Whitters' appointment, the Accuray Board has been expanded to eight members.
The Accuray CyberKnife® System empowers clinicians to make the most of their skills in treating cancer.
New Studies Show the Accuray TomoTherapy® System Provides Greater Precision, Excellent Clinical Outcomes in Patients Undergoing Total Body Irradiation
Accuray Incorporated (NASDAQ: ARAY) announced today that recently published data from two new studies demonstrate the benefits of the TomoTherapy® System in the delivery of total body irradiation (TBI), a procedure commonly used to prepare patients being treated for leukemia and multiple myeloma for a bone marrow transplant. TBI involves irradiation of the entire body, elevating the need for precision, accuracy and homogeneity in radiation dose delivery
Accuray Unveils New Company Website Reflecting Industry-Leading Patient-First Cancer Treatment Innovation and Care
Check out the new site at www.accuray.com.
Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third fiscal quarter ended March 31, 2018.